Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease

Prostate Cancer and Prostatic Diseases volume 12, pages 94–99 (2009)Cite this article

Abstract

Bone metabolic disruption that occurs in bone metastatic prostate cancer could lead to disturbances of calcium metabolism. The prognostic role of either hypocalcemia or hypercalcemia was assessed in a consecutive series of hormone-refractory bone metastatic prostate cancer patients. Serum calcium was measured in 192 patients. The presence of hypocalcemia and hypercalcemia was related with baseline biochemical and clinical characteristics and the role of these two calcium disturbances in predicting prognosis and adverse skeletal-related events (SREs) was assessed. As compared to normocalcemic patients, hypocalcemic patients (n=51) had higher tumor load in bone (P=0.005), higher plasma chromogranin A (CgA, P=0.01), serum alkaline phosphatase (P=0.01), urinary N-telopeptide (NTX, P=0.002) and lower hemoglobin values (P=0.01), while hypercalcemic patients (n=16) had higher plasma CgA (P=0.001) and serum lactate dehydrogenase values (P=0.001), higher bone pain (P=0.003) and a lower frequency of pure osteoblastic lesions (P=0.001). Hypercalcemia was significantly associated with poor prognosis: hazard ratio (HR), 1.9 (95% confidence Interval (CI) 1.2–3.3) and higher risk to develop SREs HR, 2.5 (95% CI 1.2–5.2, P=0.01), while hypocalcemia was not associated with poor prognosis. The prognostic role of hypercalcemia was maintained in multivariate analysis after adjusting for validated prognostic parameters: HR, 2.72 (95% CI 1.1–6.8, P=0.03). These data suggest that serum calcium levels should be taken into account in the clinical decision-making process of bone metastatic prostate cancer patients. Patients with asymptomatic hypercalcemia could benefit of a strict follow-up and an immediate bisphosphonate treatment. Further prospective clinical trials are needed to confirm this finding.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. De Angelis R, Capocaccia R, Verdecchia A . Estimative relative survival of Italian cancer patients from sparse cancer registries data. Tumori 1997; 83: 33–38.

    Article  CAS  PubMed  Google Scholar 

  2. Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–593.

    Article  CAS  PubMed  Google Scholar 

  3. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A . Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001; 166: 2023–2031.

    Article  CAS  PubMed  Google Scholar 

  4. Berruti A, Dogliotti L, Tucci M, Scarpa RM, Angeli A . Hyperparathyroidism due to the so called bone hunger syndrome in prostate cancer patients. J Clin Endocrinol Metab 2002; 87: 1910–1911.

    Article  CAS  PubMed  Google Scholar 

  5. Damber JE . Endocrine therapy for prostate cancer. Acta Oncol 2005; 44: 605–609.

    Article  CAS  PubMed  Google Scholar 

  6. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972–3982.

    Article  PubMed  Google Scholar 

  7. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA et al. Prognostic model for predicting survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232–1237.

    Article  PubMed  Google Scholar 

  8. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248–1253.

    Article  CAS  PubMed  Google Scholar 

  9. Clines GA, Guise TA . Hypercalcemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005; 12: 549–583.

    Article  CAS  PubMed  Google Scholar 

  10. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT . Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients (Comment). Ann Intern Med 1990; 112: 499–504.

    Article  CAS  PubMed  Google Scholar 

  11. Smith DC, Tucker JA, Trump DL . Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol 1992; 10: 499–505.

    Article  CAS  PubMed  Google Scholar 

  12. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF . Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993; 71: 1309–1317.

    Article  CAS  PubMed  Google Scholar 

  13. Wu CH, Lan YJ, Wang CH, Wu MS . Hypercalcemia in prostate cancer with positive neuron-specific enolase stain. Ren Fail 2004; 26: 325–327.

    Article  CAS  PubMed  Google Scholar 

  14. Iwamura M, Wu G, Abrahamsson PA, di Sant'agnese PA, Cockett AT, Deftos LJ . Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells. Urology 1994; 43: 67–74.

    Article  Google Scholar 

  15. Cramer SD, Chen Z, Peehl DM . Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996; 156: 526–531.

    Article  CAS  PubMed  Google Scholar 

  16. Murray LM, Grill V, Crinis N, HO PWM, Davidson J, Pitt P . Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 2001; 86: 4133–4138.

    Article  CAS  PubMed  Google Scholar 

  17. Murray TM, Rao LG, Divieti P, Bringhurt FR . Parathyroid hormone secretion and action: evidence of discrete receptors for the carboxy-terminal region and related biological actions of carboxy-terminal ligands. Endocr Rev 2005; 26: 78–113.

    Article  CAS  PubMed  Google Scholar 

  18. Lewin E, Almaden Y, Rodriguez M, Olgaard K . PTHrP enhances the secretory response of PTH to a hypocalcemic stimulus in rat parathyroid glands. Kidney Int 2002; 58: 71–81.

    Article  Google Scholar 

  19. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Guercio S, Torta M et al. Metabolic effect of single dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers 2002; 17: 244–252.

    Article  CAS  PubMed  Google Scholar 

  20. Bilezikian JP, Potts Jr JT, Fuleihan G-H, Kleerekoper M, Neer R, Peacock M et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002; 17: 2–11.

    Article  Google Scholar 

  21. Deftos LJ . Granin-A, parathyroid hormone-related protein and calcitonin gene products in neuroendocrine prostate cancer. Prostate Suppl 1998; 8: 23–31.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Oncologia Medica, Azienda Ospedaliera San Luigi di Orbassano, Torino, Italy

    M Tucci, A Mosca, G Lamanna, F Vana, L Russo, G Gorzegno, M Tampellini, M Torta, L Dogliotti & A Berruti

  2. Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Urologia, Azienda Ospedaliera San Luigi di Orbassano, Torino, Italy

    F Porpiglia, C Cracco, M Poggio & R M Scarpa

  3. Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Medicina Interna, Azienda Ospedaliera San Luigi di Orbassano, Torino, Italy

    M Terzolo, G Reimondo & A Angeli

Authors
  1. M Tucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Mosca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Lamanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Porpiglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Terzolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Vana
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Cracco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Gorzegno
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Tampellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Torta
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Reimondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Poggio
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R M Scarpa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Angeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. L Dogliotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. A Berruti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Berruti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tucci, M., Mosca, A., Lamanna, G. et al. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 12, 94–99 (2009). https://doi.org/10.1038/pcan.2008.10

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2008.10

Keywords

This article is cited by

Search

Advanced search

Quick links